Company: AZN
Filing Date: 2025-11-06
Form Type: 6-K
Source: 0001654954-25-012630
Chunk: 2

Company: ASTRAZENECA PLC
Filing Date: 2025-11-06
Form: 6-K
Chunk 2
---
 be between 18-22%

If foreign exchange rates for October 2025 to December 2025 were to remain at the average rates seen in September 2025, it is anticipated that FY 2025 Total Revenue growth and Core EPS growth would be broadly similar to the growth at CER (unchanged from the previous guidance).

http://www.rns-pdf.londonstockexchange.com/rns/3923G_1-2025-11-5.pdf

Results highlights

Table 1. Milestones achieved since the prior results announcement

Phase III and other registrational data readouts

| Medicine   | Trial            | Indication                                             | Event                      |
| Enhertu    | DESTINY-Breast05 | High-risk HER2+ early breast cancer (post-neoadjuvant) | Primary endpoint met       |
| Datroway   | TROPION-Breast02 | 1L TNBC for patients where IO is not an option         | Dual primary endpoints met |
| Imfinzi    | MATTERHORN       | Resectable gastric/GEJ cancer                          | Secondary                  
 endpoint met (OS)          |
| baxdrostat | Bax24            | Treatment resistant hypertension                       | Primary endpoint met       |
| Fasenra    | RESOLUTE         | COPD                                                   | Primary endpoint not met   |
| Saphnelo   | TULIP-SC         | SLE (subcutaneous)                                     | Primary endpoint met       |

Regulatory approvals

| Medicine  | Trial            | Indication                               | Region |
| Calquence | ECHO             | 1L MCL                                   | JP     |
| Calquence | ACE-LY-004       | Relapsed/refractory MCL                  | JP     |
| Datroway  | TROPION-Breast01 | HR+ HER2- mBC                            | CN     |
| Enhertu   | DESTINY-Breast06 | CTx naïve HER2-low and -ultralow mBC     | JP     |
| Imfinzi   | NIAGARA          | Bladder cancer                           | JP     |
| Imfinzi   | AEGEAN           | Resectable NSCLC                         | JP     |
| Lynparza  | PROpel           | BRCAm mCRPC                              | CN     |
| Tezspire  | WAYPOINT         | Chronic rhinosinusitis with nasal polyps | US, EU |
| Kos